Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

2 weeks ago 7

The German pharmaceutical-and-agricultural radical said the acquisition would complement its cause pipeline and leverage its ophthalmology footprint.